Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Simplex | 1 | 2020 | 88 | 0.680 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 344 | 0.630 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2018 | 9 | 0.610 |
Why?
|
| Magnesium Sulfate | 1 | 2018 | 17 | 0.610 |
Why?
|
| Hospital Mortality | 2 | 2021 | 779 | 0.600 |
Why?
|
| Tuberculosis, Spinal | 1 | 2017 | 6 | 0.580 |
Why?
|
| Intervertebral Disc Displacement | 1 | 2017 | 36 | 0.560 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2017 | 29 | 0.560 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 125 | 0.550 |
Why?
|
| Edema | 1 | 2017 | 119 | 0.540 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 443 | 0.530 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 486 | 0.520 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 2578 | 0.470 |
Why?
|
| Hospitalization | 3 | 2021 | 1765 | 0.460 |
Why?
|
| Bone Marrow | 1 | 2014 | 249 | 0.440 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 119 | 0.430 |
Why?
|
| MicroRNAs | 1 | 2019 | 607 | 0.420 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 538 | 0.420 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1536 | 0.410 |
Why?
|
| Rhode Island | 2 | 2021 | 23 | 0.240 |
Why?
|
| Tachypnea | 1 | 2021 | 4 | 0.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2021 | 8 | 0.190 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 16 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 116 | 0.180 |
Why?
|
| Epidemics | 1 | 2021 | 70 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 55 | 0.180 |
Why?
|
| Simplexvirus | 1 | 2020 | 82 | 0.180 |
Why?
|
| Hypotension | 1 | 2021 | 115 | 0.170 |
Why?
|
| Necrosis | 1 | 2020 | 210 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2020 | 86 | 0.170 |
Why?
|
| Fatal Outcome | 1 | 2020 | 286 | 0.170 |
Why?
|
| Comorbidity | 2 | 2021 | 1473 | 0.170 |
Why?
|
| Middle Aged | 6 | 2021 | 27014 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 139 | 0.170 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 141 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 136 | 0.160 |
Why?
|
| Triage | 1 | 2021 | 192 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2019 | 49 | 0.160 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2019 | 43 | 0.160 |
Why?
|
| Humans | 13 | 2021 | 115613 | 0.160 |
Why?
|
| Antiviral Agents | 2 | 2021 | 649 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 1001 | 0.150 |
Why?
|
| Adult | 7 | 2021 | 30726 | 0.150 |
Why?
|
| Back Pain | 1 | 2017 | 44 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 71 | 0.140 |
Why?
|
| Aged | 5 | 2021 | 19255 | 0.140 |
Why?
|
| Female | 8 | 2021 | 59932 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 391 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3023 | 0.130 |
Why?
|
| Pneumonia | 1 | 2020 | 576 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 336 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 558 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 594 | 0.120 |
Why?
|
| Male | 6 | 2021 | 55968 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 906 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1361 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1048 | 0.110 |
Why?
|
| Mutation | 1 | 2019 | 3364 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2021 | 9159 | 0.080 |
Why?
|
| Risk Factors | 1 | 2021 | 8699 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6419 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2021 | 12608 | 0.080 |
Why?
|
| Pandemics | 2 | 2021 | 1334 | 0.050 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2021 | 30 | 0.050 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 69 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2021 | 143 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 80 | 0.040 |
Why?
|
| Sirolimus | 1 | 2021 | 192 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2021 | 362 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2021 | 533 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 254 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 666 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 958 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 490 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 3339 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 4945 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6264 | 0.020 |
Why?
|